Insmed Inc (NASDAQ: INSM)’s stock price has increased by 0.66 compared to its previous closing price of 70.14. However, the company has seen a -3.10% decrease in its stock price over the last five trading sessions. prnewswire.com reported 2024-11-07 that BRIDGEWATER, N.J., Nov. 7, 2024 /PRNewswire/ — Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 27 new employees.
Is It Worth Investing in Insmed Inc (NASDAQ: INSM) Right Now?
Moreover, the 36-month beta value for INSM is 1.09. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for INSM is 174.74M and currently, short sellers hold a 7.93% of that float. On November 14, 2024, INSM’s average trading volume was 1.70M shares.
INSM’s Market Performance
The stock of Insmed Inc (INSM) has seen a -3.10% decrease in the past week, with a -5.44% drop in the past month, and a -4.77% fall in the past quarter. The volatility ratio for the week is 3.08%, and the volatility levels for the past 30 days are at 3.11% for INSM. The simple moving average for the last 20 days is -1.00% for INSM stock, with a simple moving average of 33.18% for the last 200 days.
Analysts’ Opinion of INSM
Many brokerage firms have already submitted their reports for INSM stocks, with Truist repeating the rating for INSM by listing it as a “Buy.” The predicted price for INSM in the upcoming period, according to Truist is $48 based on the research report published on April 23, 2024 of the current year 2024.
Wolfe Research, on the other hand, stated in their research note that they expect to see INSM reach a price target of $42. The rating they have provided for INSM stocks is “Outperform” according to the report published on February 15th, 2024.
Wells Fargo gave a rating of “Overweight” to INSM, setting the target price at $55 in the report published on December 08th of the previous year.
INSM Trading at -2.30% from the 50-Day Moving Average
After a stumble in the market that brought INSM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.33% of loss for the given period.
Volatility was left at 3.11%, however, over the last 30 days, the volatility rate increased by 3.08%, as shares sank -7.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.18% lower at present.
During the last 5 trading sessions, INSM fell by -3.10%, which changed the moving average for the period of 200-days by +143.70% in comparison to the 20-day moving average, which settled at $71.31. In addition, Insmed Inc saw 127.82% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INSM starting from Smith Michael Alexander, who sale 27,871 shares at the price of $74.35 back on Sep 13 ’24. After this action, Smith Michael Alexander now owns 67,856 shares of Insmed Inc, valued at $2,072,223 using the latest closing price.
Flammer Martina M.D., the Chief Medical Officer of Insmed Inc, sale 26,969 shares at $74.90 during a trade that took place back on Sep 13 ’24, which means that Flammer Martina M.D. is holding 106,134 shares at $2,019,978 based on the most recent closing price.
Stock Fundamentals for INSM
Current profitability levels for the company are sitting at:
- -2.14 for the present operating margin
- 0.77 for the gross margin
The net margin for Insmed Inc stands at -2.52. The total capital return value is set at -0.41. Equity return is now at value -890.75, with -51.17 for asset returns.
Based on Insmed Inc (INSM), the company’s capital structure generated 0.67 points at debt to capital in total, while cash flow to debt ratio is standing at -0.62. The debt to equity ratio resting at 2.07. The interest coverage ratio of the stock is -18.88.
Currently, EBITDA for the company is -654.74 million with net debt to EBITDA at -0.7. When we switch over and look at the enterprise to sales, we see a ratio of 38.4. The receivables turnover for the company is 8.1for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.37.
Conclusion
To wrap up, the performance of Insmed Inc (INSM) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
